Houston-first directory · 6 checked local clinicians · No patient lead forms
← FDA shortage tracker

Semaglutide

Regulatory registry

Context
FDA-approved product context; compounded versions not approved
Reason / limits
Wegovy injection and tablets have different labeled populations and indications.
Last source review
October 15, 2026
Review scope
Regulator source and the product/route limits described below rechecked October 15, 2026.
Clinical phase
Unknown: no current trial-specific phase check is included in this registry.
Registry NDC / manufacturer
Unknown unless linked to a matched FDA package record below.

Research-only means this library makes no approved-treatment claim. Compounding context does not mean compounded-only, authorized for compounding, or legally available. Product-specific source limits control.

Regulatory sources

Original regulatory / editorial source

Original regulatory / editorial source

Read the full evidence note

FDA shortage tracker

Approval context and shortage status are separate. An NDC identifies a package; it does not establish FDA approval or permission to compound.

Discontinuation / mixed records

Matched records include discontinuation notices or mixed non-current states. Check each package; no compound-wide stock conclusion is made.

FDA dataset: 2026-10-16. Retrieved: Oct 16, 2026, 1:45 PM CDT.

Full dated shortage record · All compound tracker entries

Matched package records (3)

Records match a single exact active substance. Route and presentation are shown separately; a record does not apply to every product or preparation.

Semaglutide Tablet

Package NDC
0169-4307-30
Manufacturer
Novo Nordisk, Inc.
Product / route
RYBELSUS / ORAL
FDA record status
To Be Discontinued
Reported availability
Unknown
FDA reason
Not supplied
FDA record updated
06/04/2026

FDA API record for this package

Semaglutide Tablet

Package NDC
0169-4303-30
Manufacturer
Novo Nordisk, Inc.
Product / route
RYBELSUS / ORAL
FDA record status
To Be Discontinued
Reported availability
Unknown
FDA reason
Not supplied
FDA record updated
06/04/2026

FDA API record for this package

Semaglutide Tablet

Package NDC
0169-4314-30
Manufacturer
Novo Nordisk, Inc.
Product / route
RYBELSUS / ORAL
FDA record status
To Be Discontinued
Reported availability
Unknown
FDA reason
Not supplied
FDA record updated
06/04/2026

FDA API record for this package

Observed change history (1)

Observed dates are when our sync saw a source state, not when a shortage started or ended. Unchanged daily checks do not add duplicate events.